沙美特罗昔萘酸盐与环索奈德共无定形物及其制备方法和应用
By preparing co-amorphous and nano-co-amorphous compounds of salmeterol roxonaphthyl acid salt and cyclosonepine, the problems of poor water solubility and dispersibility were solved, resulting in better solubility and stability, and enhanced drug synergy. This method is suitable for preparing drugs for the prevention or treatment of obstructive airway diseases.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- EAST CHINA UNIV OF SCI & TECH
- Filing Date
- 2024-12-27
- Publication Date
- 2026-07-17
AI Technical Summary
The combination of salmeterol roxonaphthyl acid salt and ccyclosone is difficult to manufacture due to its extremely low water solubility and dispersibility, making it hard to achieve effective synergistic anti-inflammatory and bronchodilator effects.
Amorphous and nano-amorphous compounds of salmeterol roxenamate and cyclosonepine were prepared. The amorphous compounds were formed by rotary evaporation or grinding, and the nano-amorphous compounds were prepared by freeze-drying with emulsified solvents to improve their solubility and stability.
It significantly improved the solubility and dissolution rate of salmeterol roxonaphthyl salt and ccyclosone, achieving simultaneous release of the two components and enhancing the synergistic anti-inflammatory and bronchodilatory effects, making it suitable as an API for combination therapy.
Smart Images
Figure BDA0005215594140000011 
Figure BDA0005215594140000021 
Figure BDA0005215594140000151